Sign in
Create a Profile
Ziprasidone in the Psychosis Prodrome
Diseases and Conditions Researched
Psychosis Prodrome
What is the purpose of this trial?
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Yale University |
|---|---|
| Dates: | March 6, 2008 |
| Last Updated: | January 13, 2010 |
| Study HIC#: | 0801003386 |
| Clinicaltrials.gov ID: | NCT00635700 |
How will my information be used?
For more information about this trial, contact:
Barbara Walsh, PhD
203-974-7052
barbara.walsh@yale.edu
John R Saksa, Psy.D.
203 974 7043
john.saksa@yale.edu
Scott Woods, MD
203-974-7038
scott.woods@yale.edu
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
